Our Clinicians

Alison T. Stopeck, MD

Associate Professor of Medicine

EDUCATION

Medical School: Columbia University College of Physicians & Surgeons, New York, NY
Residency: Internal Medicine, Columbia Presbyterian Medical Center , New York , NY
Fellowship: Hematology/Oncology, Cornell University Medical College, New York, NY

PROFESSIONAL EXPERIENCE

Cornell University Medical College, New York , NY
Instructor, Medicine 1991-1992
Assistant Professor, Medicine 1992-1993

The University of Arizona, Arizona Cancer Center, Tucson, AZ
Assistant Professor of Clinical Medicine 1993-1997
Assistant Professor of Medicine 1997-2002
Associate Professor of Medicine 2002-present

University Medical Center
Medical Director, Coagulation Laboratory 1995-present
Mountain State Regional Hemophilia Center
Adult Hemophilia Director 1993-present

SELECTED PUBLICATIONS

Altbach MI, Outwater EK, Trouard TP, Krupriski EA, Thielmann RJ, Stopeck AT, Kono M, Gmitro F. Radial fast spin-echo method for T2-weighted MR imaging and T2 mapping of the liver. J Magn Reson. 2002;16:179-189.

Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002;169:1829-1836.

Stopeck AT , Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002;8:2798-2805.

Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantjarian HM, Stopeck AT. Phase II study of SU5416-a small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer. 2003;97:1920-1928.

Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O’Farrell A-M, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O’Brien SM, Kantarjian HM. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug;102:795-801.

Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 January;10:88-95.

O’Farrell AM, Yuen HA, Smolich B, Hannah AL, Louise SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, oh FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul;28:679-689.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug;351:781-791.

Theilmann R, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies R, Stopeck A. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia. 2004 Dec;6(6):831-837.

Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2004 Mar;23(7):1420-1430.

Division of Women's Cancers
Arizona Cancer Center
1515 N. Campbell Ave.
PO Box 245024
Tucson, AZ 85724-5024
Phone: 520-626-0950
Fax: 520-626-8574
E-mail: sskszek@azcc.arizona.edu

	Our Clinicians Alison T. Stopeck, MD Associate Professor of Medicine EDUCATION Medical School: Columbia University College of Physicians & Surgeons, New York, NY Residency: Internal Medicine, Columbia Presbyterian Medical Center , New York , NY Fellowship: Hematology/Oncology, Cornell University Medical College, New York, NY PROFESSIONAL EXPERIENCE Cornell University Medical College, New York , NY Instructor, Medicine 1991-1992 Assistant Professor, Medicine 1992-1993 The University of Arizona, Arizona Cancer Center, Tucson, AZ Assistant Professor of Clinical Medicine 1993-1997 Assistant Professor of Medicine 1997-2002 Associate Professor of Medicine 2002-present University Medical Center Medical Director, Coagulation Laboratory 1995-present Mountain State Regional Hemophilia Center Adult Hemophilia Director 1993-present SELECTED PUBLICATIONS Altbach MI, Outwater EK, Trouard TP, Krupriski EA, Thielmann RJ, Stopeck AT, Kono M, Gmitro F. Radial fast spin-echo method for T2-weighted MR imaging and T2 mapping of the liver. J Magn Reson. 2002;16:179-189. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002;169:1829-1836. Stopeck AT , Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002;8:2798-2805. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantjarian HM, Stopeck AT. Phase II study of SU5416-a small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer. 2003;97:1920-1928. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O’Farrell A-M, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O’Brien SM, Kantarjian HM. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug;102:795-801. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 January;10:88-95. O’Farrell AM, Yuen HA, Smolich B, Hannah AL, Louise SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, oh FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul;28:679-689. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug;351:781-791. Theilmann R, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies R, Stopeck A. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia. 2004 Dec;6(6):831-837. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2004 Mar;23(7):1420-1430.
Home Appointments Our Clinicians Research Cancer by Site Links
Division of Women's Cancers Arizona Cancer Center 1515 N. Campbell Ave. PO Box 245024 Tucson, AZ 85724-5024 Phone: 520-626-0950 Fax: 520-626-8574 E-mail: sskszek@azcc.arizona.edu
	All contents ©2005 Arizona Board of Regents. All rights reserved. The University of Arizona is an EEO/AA - M/W/D/V Employer.